Drug discovery is one of the most complex and costly processes in the pharmaceutical industry. The need to simultaneously optimize multiple parameters —such as efficacy, toxicity, bioavailability, and stability— has driven the adoption of machine learning (ML) models that assist scientists at every stage of the Design-Make-Test-Analyze cycle. However, managing these models in production is not trivial. Traditional Machine Learning Operations (MLOps) platforms are designed for generic environments and do not cover the specificities of the pharmaceutical domain: inference-time composition of multiple models for multi-parameter optimization, version management for physics-based models without serialized ML artifacts, enterprise compound library precomputation, and governance structured around scientific organizational units rather than generic access controls.
In this context, Eli Lilly has developed and deployed the Model Gateway, a cloud platform that centralizes the management of ML and scientific computational models across drug discovery pipelines. In production, the system governs more than 200 deployed models spanning small molecule, peptide, and antibody modalities, serving more than five downstream applications across all phases of the cycle. Model Gateway provides centralized version control, pharma-structured governance, asynchronous execution, consensus model orchestration, automated retraining, and a unified API for heterogeneous clients ranging from molecular design suites to Large Language Model (LLM) agents.
This architecture solves critical problems that no commercial or open-source platform addresses simultaneously. For example, the ability to compose multiple models at inference time allows computational chemists to evaluate hundreds of properties at once, accelerating candidate selection. Specialized versioning for physics-based models —which lack serialized ML artifacts— ensures reproducibility of molecular dynamics simulations or docking. Furthermore, governance structured by scientific organizational units (medicinal chemistry teams, structural biology, DMPK, etc.) facilitates collaboration and regulatory compliance without the overhead of administering generic role-based access control systems.
Implementing such a platform requires deep knowledge of both the pharmaceutical domain and cloud and artificial intelligence technologies. This is where companies like Q2BSTUDIO provide differential value. With solid experience in developing AI-based applications and building scalable cloud infrastructures, Q2BSTUDIO helps organizations of all types design and deploy model management systems that meet the most demanding requirements. The company offers custom software that integrates machine learning models, cloud services on AWS/Azure, cybersecurity solutions to protect sensitive research data, and BI/Power BI tools to visualize model performance metrics and experiment results.
One of the most innovative aspects of Model Gateway is consensus model orchestration. Instead of relying on a single predictive model, the platform executes multiple models trained with different approaches (neural networks, random forests, physics-based models) and combines their predictions through voting or weighted averaging strategies. This reduces bias and improves prediction robustness, a critical factor when deciding which compound to synthesize and test. Asynchronous execution allows launching these evaluations in parallel on elastic cloud infrastructure, optimizing costs and response times. Automated retraining ensures models are periodically updated with new experimental data, maintaining accuracy over time.
Another key pillar is the unified API. Both molecular design suites (such as Schrödinger or MOE) and LLM agents (increasingly used for generating hypotheses or planning syntheses) can consume the same inference services without complex adaptations. This democratizes access to models and fosters collaboration among multidisciplinary teams. Additionally, governance structured by scientific units allows each team to manage its own models, versions, and permissions within a coherent corporate framework, facilitating audits and compliance with regulations like GxP or 21 CFR Part 11.
From a cybersecurity perspective, working with pharmaceutical research data involves protecting highly sensitive information about compounds, therapeutic targets, and trial results. Q2BSTUDIO integrates cloud services on AWS and Azure with encryption mechanisms, identity management, and policy-based access controls, ensuring only authorized users can access models and data. Furthermore, Q2BSTUDIO's cybersecurity solutions include continuous pentesting and threat monitoring, protecting the pharmaceutical company's intellectual property.
Business intelligence also plays a relevant role. Discovery pipelines generate enormous volumes of data: screening results, calculated properties, model performance metrics, etc. With BI tools like Power BI, Q2BSTUDIO develops dashboards that allow scientists and managers to visualize trends, identify bottlenecks, and make data-driven decisions. For example, a dashboard can show the hit rate of models across different cycle phases, facilitating resource prioritization.
In summary, Model Gateway represents a significant advance in model management for drug discovery, but its success depends on a robust and customized architecture. Companies like Q2BSTUDIO, specialized in custom software development, artificial intelligence, cloud, cybersecurity, and BI, are the ideal partner to implement similar solutions in any organization seeking to accelerate scientific innovation while maintaining control and security. The convergence of machine learning models, generative AI agents, and cloud platforms is redefining how new drugs are discovered and developed, and having the right infrastructure makes the difference between leading or following in this highly competitive field.
